Al-Ola A Abdallah

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Al-Ola A Abdallah
May 1, 2025, 10:25 | Science
Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy
Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT…
Apr 21, 2025, 10:27 | Blog
Al-Ola A Abdallah: Medicare Part D Prescriber Look-up Tool
Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of…
Apr 11, 2025, 11:29 | Blog
Al-Ola A Abdallah: Main Speakers are ready for the 2025 National ICE-T Conference
Al-Ola A Abdallah, Associate Professor and Plasma Cell disorder program Director at University of Kansas Medical…
Mar 16, 2025, 11:25 | Blog
Al-Ola A Abdallah: Daratumumab-Based Quadruplet vs. Triplet Induction Regimens in Transplant-Eligible NDMM
Al-Ola A Abdallah, Associate Professor and Plasma Cell disorder program Director at University of Kansas…
Mar 4, 2025, 06:27 | Drugs
Al-Ola A Abdallah: Targeted interferon therapy with modakafusp alfa for R/R multiple myeloma
Al-Ola A Abdallah, Associate Professor and Plasma Cell disorder program Director at University of Kansas Medical…
Mar 3, 2025, 12:59 | Blog
Al-Ola A Abdallah: Chemotherapy-Induced Peripheral Neuropathy Hematological Patients
Al-Ola A Abdallah, Associate Professor and Plasma Cell disorder program Director at University of Kansas…
Feb 9, 2025, 15:37 | Science
Al-Ola A Abdallah: Clinicopathologic Predictors of Renal Response and Survival in NDMM with Renal Impairment
Al-Ola A Abdallah, Associate Professor and Plasma Cell disorder program Director at University of Kansas…
Jan 22, 2025, 09:11 | Insight
Al-Ola A Abdallah: Insights into bispecific T-cell engagers
Al-Ola A Abdallah, Associate Professor, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas…
Jan 20, 2025, 13:23 | Blog
Al-Ola A Abdallah: Comparing Idecabtagene Vicleucel and Ciltacabtagene Autoleucel for RRMM
Al-Ola A Abdallah, Associate Professor, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas…
Jan 13, 2025, 09:37 | Science
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center, shared…
Dec 11, 2024, 19:11 | Drugs
Results of AQUILA Trial: Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for treating multiple myeloma. On December 9th…
Dec 10, 2024, 16:55 | Societies
Highlights from Day 3 of ASH 2024
The 66th ASH Annual Meeting and Exposition held from December 7-10, 2024, in San Diego,…
Dec 7, 2024, 11:45 | Blog
Al-Ola A Abdallah: Celebrating mentees matching in Heme-Onc Fellowship
Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center,…
Nov 25, 2024, 18:11 | Insight
Al-Ola A Abdallah: Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma
Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center,…
Oct 26, 2024, 12:33 | Insight
Al-Ola A Abdallah: Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?
Al-Ola A Abdallah, Associate Professor, Plasma Cell disorder program Director, Division of HMCT at University…
Aug 27, 2024, 23:06 | Blog
Al-Ola A Abdallah: What's the best approach after M protein reappearance in high-risk Smoldering Myeloma?
Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center,…
Jul 29, 2024, 06:08 | Blog
Nausheen Ahmed: KUICE-T kicks off with the reception at KU Cancer Center
Nausheen Ahmed, Medical Director of BMT Survivorship Program at The University of Kansas, shared a…
Jul 28, 2024, 15:37 | Insight
Timing of Toxicities and Mortality Following CAR T Therapy in Myeloma
Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center,…
Jul 25, 2024, 20:13 | Insight
Optimizing the Post-CAR T Monitoring Period
Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director at Division of HMCT/University…
Jun 24, 2024, 22:06 | Blog
Nausheen Ahmed: Approvals, toxicity and access updates on CART
Nausheen Ahmed, Medical Director of BMT Survivorship Program at The University of Kansas, shared a…
May 21, 2024, 13:21 | Insight
Rahul Banerjee: Two-for-one with new MMsm articles in press in Transplantation and Cellular Therapy Journal
Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, shared…
Feb 12, 2024, 01:59 | Blog
Al-Ola A Abdallah: Did the FDA Oncology make a big mistake by withdrawing Belantamab?
Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center,…
All: 22 Posts: 1 - 100
Special Coverage